Literature DB >> 11109771

[Detection of rifampin-resistant Mycobacterium tuberculosis by line probe assay (LiPA)].

C Abe1, H Ogata, K Kawata, T Hiraga, T Takashima, T Suetake.   

Abstract

A recently described reverse hybridization-based line probe assay is used for the rapid detection of the mutations in the rpoB genes of rifampin-resistant Mycobacterium tuberculosis and for the identification of the M. tuberculosis complex. A multicenter study that included 5 laboratories was performed to evaluate the line probe assay in comparison with the in vitro susceptibility test. A total of 406 mycobacteria isolates which were composed of 103 rifampin-resistant and 230 rifampin-susceptible M. tuberculosis isolates, and 73 mycobacteria other than tubercle bacilli (MOTT), were subjected to this study. All 333 M. tuberculosis isolates were discriminated correctly from MOTT bacilli by a line probe assay. Concordance rates with sequencing results for five wild-type probes (S probes) and four specific mutations (R probes) for detecting the mutations in the rpoB genes were both 100%. The overall concordance rate with the in vitro susceptibility testing results was 98.5% (328 of 333 isolates). These results indicate that a line probe assay kit may be useful for the rapid diagnosis of rifampin-resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11109771

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  2 in total

1.  Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility.

Authors:  E Tortoli; F Marcelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

2.  Development and Comparison of In-house Line Probe Assay (LiPA) and SYBR Green Real-time PCR Regarding the Detection of Periodontal Pathogens.

Authors:  Mohammad Soleimani; Mohammad Reza Zolfaghari
Journal:  Avicenna J Med Biotechnol       Date:  2019 Jan-Mar
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.